GlassScriptPhysician profile
Peter A Swaby
NPI 1508972266
$12,282.62
in general payments reported to CMS, 2019-2025
51 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $1,089 · 2021: $1,425 · 2022: $1,972 · 2023: $2,134 · 2024: $1,945 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,125 · Education: $44.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,125.03 |
| Education | $44.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,884.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,438.48 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,381.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $1,170.58 | 2019-2025 | Biktarvy, Sunlenca |
| Lilly USA, LLC | $1,036.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $554.83 | 2019-2025 | |
| Viiv Healthcare Company | $516.17 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Glaxosmithkline, LLC. | $460.98 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $400.81 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $345.21 | 2019-2024 | Delstrigo |
| Amgen INC. | $290.58 | 2019-2025 | Repatha |
| Kowa Pharmaceuticals America, INC. | $267.60 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.36 | 2020-2025 | Jardiance |
| Corcept Therapeutics | $176.78 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $128.02 | 2019-2025 | Trintellix |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Swaby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.